BioAlliance Pharma Presents Phase III Results with Loramyc(R) (Miconazole Lauriad(R)) and Ongoing Phase II Trial with Clonidine Lauriad(R)
PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Paris:BIO), a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.